A Framework for Discussion on How to Improve Prevention, Management, and Control of Hypertension in Canada

Campbell, Norm R.C.; Young, Eric; Drouin, Denis; Legowski, Barbara; Adams, Michael A.; Farrell, Judi; Kaczorowski, Janusz; Lewanczuk, Richard; Lum-Kwong, Margaret Moy; Tobe, Sheldon

doi:10.1016/j.cjca.2011.11.008

Cited by 52 publications

(78 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hypertension is one of the leading risks for premature death and disability universally. Recent analyses have shown that the number of adults with hypertension in 2025 was predicted to increase by about 60% to a total of 1.56 billion (Kearney et al, 2005;Chockalingam et al, 2006;Campbell et al, 2012). Overall, hypertension is an important publichealth challenge globally.…”

Section: Resultsmentioning

confidence: 99%

Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension

et al. 2014

View full text Add to dashboard Cite

Context: Angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) are some of the most commonly prescribed medications for hypertension. Objective: Most of all conventional dosage forms of ARBs and ACEIs undergo extensive first-pass metabolism, which significantly reduces bioavailability. Majority of ARBs and ACEIs are inherently short acting due to a rapid elimination half-life. In addition, oral dosage forms of ARBs and ACEIs have many high incidences of adverse effects due to variable absorption profiles, higher frequency of administration and poor patient compliance. Methods: Many attempts have been made globally at the laboratory level to investigate the skin permeation and to develop transdermal therapeutic systems of various ARBs, ACEIs and other anti-hypertensives, to circumvent the drawbacks associated with their conventional dosage form. Results: This manuscript presents an outline of the transdermal research specifically in the area of ARBs, ACEIs and other anti-hypertensives reported in various pharmaceutical journals. Conclusion: The transdermal delivery has gained a significant importance for systemic treatment as it is able to avoid first-pass metabolism and major fluctuations of plasma levels typical of repeated oral administration. As we can experience from this review article that transdermal delivery of different ARBs and ACEIs improves bioavailability as well as patient compliance by many folds. In fact, the rationale development of some newer ARBs, ACEIs and other anti-hypertensives transdermal systems will provide new ways of treatment, circumventing current limitations for conventional dosage forms.

show abstract

Section: Resultsmentioning

confidence: 99%

Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The trajectory for further improvements in blood pressure diagnosis and control rates is flattening. Strategic planning in 2011 outlined in the Hypertension Framework, a document which outlined a public policy approach to preventing hypertension and improving hypertension control, provided targets for improving hypertension prevention and control to be achieved by 2020 (12). There has been little to no progress towards those targets.…”

mentioning

confidence: 99%

Hypertension in Canada and the Global Context. The Wine Is Vintage and the Glass Is Two-Thirds Full, but Is the Bottle Empty?

Campbell

Feldman

2016

Canadian Journal of Cardiology

View full text Add to dashboard Cite

“…[1][2][3][4][5] For example, the Royal College of Physicians and Surgeons of Canada competency framework (CanMEDS) identifies physicians as health advocates with an individual and collective responsibility to use their expertise and influence to advance the health and well-being of individual patients, communities, and populations. 6 In Canada, as in most industrialized countries, preventable cardiovascular disease, diabetes, cancer, and chronic respiratory disease account for roughly two thirds of all deaths each year.…”

mentioning

confidence: 99%

Death by Diet: The Role of Food Pricing Interventions as a Public Policy Response and Health Advocacy Opportunity

Duhaney

Campbell

Niebylski

et al. 2015

Canadian Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

A Framework for Discussion on How to Improve Prevention, Management, and Control of Hypertension in Canada

Cited by 52 publications

References 30 publications

Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension

Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension

Hypertension in Canada and the Global Context. The Wine Is Vintage and the Glass Is Two-Thirds Full, but Is the Bottle Empty?

Death by Diet: The Role of Food Pricing Interventions as a Public Policy Response and Health Advocacy Opportunity

Contact Info

Product

Resources

About